BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.

about

MYC Deregulation in Primary Human Cancers.Differential Expression of Circular RNAs in Glioblastoma Multiforme and Its Correlation with Prognosis.Anticancer Drug-Induced Acute Kidney Injury.

P2860

Q33836755-D72BBC5A-0D75-4858-87C0-2518AF707365 Q37670212-28C5BB46-4393-499A-9472-6C1B094916B4 Q47261056-8760D4DA-166C-4D3D-8338-351AD003461E

P2860

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.

Item

http://www.wikidata.org/entity/Q38919639

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.

@en

type

Item

label

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.

@en

prefLabel

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.

@en

P1476

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities

@en

P2093

Daniela Rizzo

http://www.w3.org/2001/XMLSchema#string

Maria Amato

http://www.w3.org/2001/XMLSchema#string

Palma Maurizi

http://www.w3.org/2001/XMLSchema#string

Riccardo Riccardi

http://www.w3.org/2001/XMLSchema#string

P2860

Profiling critical cancer gene mutations in clinical tumor samples

Recurrent BRAF mutations in Langerhans cell histiocytosis

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

To BRAF or not to BRAF: is that even a question anymore?

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

P304

1397-1405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17425255.2016.1214710

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Ruggiero

P577

2016-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27494648

http://www.w3.org/2001/XMLSchema#string

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.

about

P2860

P2860

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698